IFI27 Antibody

Treatment of breast carcinoma MCF7cells with estradiol led to induction of a new 27 kDa protein, the cDNA was later cloned and identified as p27. This highly hydrophobic protein of 122 amino acids has 33% over all sequence similarity to the product of the 6-16 gene (1), that is induced by alfa/beta type interferons. It has been shown that p27is transcriptionaly induced by interferon alfa in various human cell lines. The induction induced by interferon alfa is independent of the presence of estradiol receptors on the cells. High levels of p27 mRNA, detected by Northern blotting, was found in 50% of the primary breast carcinoma cells, suggesting p27 can be a diagnostic marker for breast carcinoma detection (2). Examination of p27 expression by in situ hybridization in p27 over expressing tumors suggest that p27 gene is localized in cancer cells and some times also in fibroblastic cells of tumor stroma. IFI27 mRNA expression is highly up-regulated in lesional psoriatic epidermis and in non-lesional keratinocytes. It was also expressed in lichen planus, chronic eczema, cutaneous squamous cell cancers, and during normal wound repair when IFI27 was found in the proliferating subpopulation of keratinocytes (3). P27 Further studies are now necessary to elucidate the cause of p27 gene overexpression in breast carcinoma and in particular to determine whether it corresponds to chromosomal rearrangements in the 14q32 region and/or to induction by interferons of the alpha/beta type.

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Array NB300-709

• IFI27 Antibodies
• IFI27 Lysate
• IFI27 Protein